Kaposi sarcoma (KS) occurs as a result of Kaposi sarcoma-associated herpesvirus (KSHV) infection, typically in the context of one of several immunodeficient states. In the US, patients with KS may either be co-infected with HIV or receiving immunosuppressant therapy following solid-organ transplantation. Systemic treatment of KS has traditionally involved one of several chemotherapeutic agents administered either in combination or as single agents, which typically provide reasonable response rates and short-term control. However, recurrence of KS is common, and progression-free intervals are under 1 year. For these reasons, new therapies have been sought and with the elucidation of novel pathogenic mechanisms of KS infection, rational therapeutic targets have been identified. These include KSHV replication, restoration of immune competence, and signal transduction pathways utilized by KSHV in the propagation of KS. This review focuses on these emerging targets in the treatment of patients with KS and also highlights important clinicopathologic characteristics.
Clinical Characteristics and Standard Therapy
KS is a multifocal, angioproliferative neoplasm that occurs in several clinical-epidemiologic settings. It is the most common tumor in HIV-infected patients and is a leading cause of mortality and morbidity in AIDS. [4] Tumorigenesis is driven by KSHV infection, predominantly in individuals who are immunosuppressed. Clinical subtypes include (i) classic KS, a disease that mainly affects elderly Mediterranean men; (ii) iatrogenic KS, which develops in patients taking immunomodulatory agents in the context of solid-organ transplantation; and (iii) AIDS-related KS. [5] [6] [7] African KS is endemic to Africa and unrelated to HIV infection. KSHV infection and an ineffective host immune response toward this g herpes virus are common to all of the aforementioned KS clinical subtypes. Reversal of immune suppression, either with highly active antiretroviral therapy (HAART) or by decreasing the dose levels of immunomodulatory agents in transplant recipients, has been associated with regression of lesions. [8, 9] In addition, the incidence of KS has decreased over 6-fold with the advent of the widespread use of HAART in HIV-infected individuals. [10] Despite a decrease in incidence, KS remains a disease with a wide spectrum of severity, ranging from single skin or mucosal lesions to rapidly progressing, extensive cutaneous, and or visceral manifestations. For patients with advanced disease, systemic therapy is indicated, and three US FDA-approved agents are available. These include the liposomal anthracyclines (PEGylated liposomal doxorubicin [PLD] and liposomal daunorubicin) and the taxane paclitaxel. PLD use is associated with response rates ranging from 46% to 59% and a median duration of response ranging from 3 to 5 months. [11, 12] In patients with AIDS-related KS, treatment with liposomal daunorubicin has been associated with an overall response rate of 25%, disease stability in 62%, a median duration of response of 175 days, and a median time to progression of 115 days. [13] Both liposomal anthracyclines have been associated with limited toxicity and have been better tolerated than a regimen of doxorubicin-bleomycin-vincristine in two clinical trials and bleomycin-vincristine in a separate clinical trial. [11] [12] [13] Paclitaxel received FDA approval based on the results of a phase II trial in 28 patients with advanced HIV-associated KS and significant immunosuppression (mean CD4+ cell count 15 cells mL); 20 of 28 patients showed a major response to treatment. [14] The mean progression-free survival was 6.3 months and the median duration of response was 7.4 months; grade 3 and 4 toxicity were reported to be rare. Despite the effectiveness of these agents, most patients with KS progress within 6-7 months of treatment and require additional therapy. Although patients may initially benefit from further cycles of chemotherapy, durable chemotherapy-free remissions tend to be shorter with each successive treatment regimen. Clearly, novel therapeutic strategies are needed.
Key Pathologic Findings
KS lesions, of all epidemiologic forms, consist of KSHV positive (latent nuclear antigen-1 immunoreactive) spindledshaped tumor cells, vessels, and chronic inflammatory cells (figure 1). KS lesions evolve from early patches to plaques, then tumor nodules. Early patch lesions are characterized by a proliferation of irregular, thin-walled vascular channels. As the cellularity of the lesion increases, a palpable plaque forms. Continued proliferation of spindle cells eventually results in a nodular tumor. Rarely, KS can regress spontaneously but, as alluded to in section 1, regression is seen most often following appropriate therapy or after discontinuation of immunosuppressive therapy. [15] KS flare (or exacerbation) can occur as part of the immune reconstitution inflammatory syndrome (IRIS) following HAART, and after treatment with corticosteroids and rituximab. [16] The unique staging systems available for classic and AIDS-associated KS (e.g. the AIDS Clinical Trials Group staging classification) [17] are used for clinicalpathologic classification of tumors in clinical trial patients.
Targeting Kaposi Sarcoma-Associated Herpesvirus (KSHV)
Like all herpesviruses, the KSHV life cycle includes a latent phase and a lytic phase. Gene expression in the latent phase is limited, even though these gene products play an important role in oncogenesis. [18] The lytic phase is characterized by the expression of many genes that culminate in viral replication followed by cell lysis and the release of viral replicants. It is during this lytic phase that KSHV is susceptible to the effects of antiviral agents. [19] Notably, in KS lesions, only a small percentage of cells are infected with KSHV in the lytic phase, but the great majority of the cells harbor KSHV in the latent phase. [20] By comparison, in KSHV-related MCD, a much greater degree of KSHV lytic gene expression is seen in lesional tissue. [21] Given its causal role in KS, there has been great optimism that therapy aimed directly at KSHV may provide benefit in the treatment of KS. Several antiviral agents, including ganciclovir, foscarnet, and cidofovir, have been shown to inhibit KSHV replication in vitro, and a randomized controlled trial has recently established the efficacy of valganciclovir in reducing KSHV replication. [22, 23] In addition, a trend toward a lower incidence of KS has been reported in cytomegalovirus-infected patients with concomitant HIV treated with ganciclovir and foscarnet but not aciclovir, which has little in vitro activity against KSHV. [24] However, this has not translated into successful therapeutic use of these antiviral agents in KS.
Specifically, cidofovir was shown to be ineffective in the treatment of patients with KS. [25, 26] This is in contrast to reports of improvement in patients with MCD treated with ganciclovir. [27] Also, cases of prolonged survival in persons with PEL treated adjunctively with ganciclovir or cidofovir have been reported. [28, 29] The reason for this variable activity of antiviral therapy for each of the KSHV-associated diseases is unclear but most likely lies in the relative proportion of lyticphase virus present in each disease. [19] Histone deacetylase (HDAC) inhibitors are agents capable of inducing lytic replication in latently infected cells. [30] The HDAC inhibitor valproic acid was initially shown to induce lytic replication of KSHV in cultured PEL cells. [31] This was followed by a pilot clinical trial of valproic acid in patients with AIDSassociated KS receiving HAART. [32] Although only 1 of 18 patients (6%) showed a partial response after short-course treatment, none of the patients in this study had KS progression. This pilot study supports further research of more potent HDAC inhibitors over longer treatment courses in patients with KS.
Targeting KSHV-Directed Immunity
The regression of KS with a reduction in immunosuppressive treatment following solid organ transplant, and the clinical improvement of KS in subjects with immune reconstitution associated with HAART, provide evidence that the immune system plays a critical role in the control of KS. The exact mechanisms of interaction of the immune system with KSHV-infected cells, or its oversight of the clinical regression of KS mentioned in section 1, have been elucidated. What is clear is that diminished immune status is a critical contributing factor to KS development, and its improvement is an important therapeutic goal.
Highlighting this approach is the effectiveness of antiretroviral regimens in treating AIDS-related KS. This strategy is so important that it is considered standard practice for all patients with AIDS-associated KS to receive HAART when available. [8] This is based on the fact that HAART is associated with both a reduction in the incidence of AIDS-related KS and regression in the size and number of existing lesions. [33, 34] It is difficult to know the exact rate of response of patients with KS to HAART alone, since in many patients with advanced KS, cytotoxic chemotherapy is administered concurrently. While there are minimal data comparing the efficacy of various HAART regimens in the treatment of KS, the use of protease-inhibitor-containing regimens has a theoretical advantage based on experimental models and anecdotal data. [35] Discontinuation of chemotherapy without subsequent KS recurrence can be achieved in certain individuals with more advanced KS once their HIV infection is successfully suppressed with effective HAART.
In patients with iatrogenic (transplant-associated) KS, reduction of immunosuppression, while not always feasible, is desired. [9] In patients where such reductions would incur undue risk (e.g. graft rejection), changes in the immunomodulatory regimen may be warranted. For example, a series of patients had notable regression of KS when the ciclosporin-based regimens on which they developed KS were changed to one that included sirolimus. [36] While the degree of immunosuppression was likely unaltered based upon the absence of graft rejection in these patients, the improvement documented was more likely the result of inhibiting constitutively active KSHV-mediated signal transduction. The use of sirolimus and its analogs in the treatment of patients with KS is discussed in section 5.
Targeting KSHV-Mediated Signaling
Through intricate and varied utilization of critical signal transduction pathways, KSHV gene products drive the transformation of KSHV-infected cells into KS lesions. Some of these virally encoded proteins are cellular homologs of oncogenes that play critical roles in cell cycle regulation and apoptosis. Others are homologs of cytokines, chemokines, or chemokine receptors that promote cellular growth and transformation when abnormally regulated. The ramification of activating these proteins and oncogenic pathways include abnormal regulation of the cell cycle, promotion of angiogenesis, and propagation of an antiapoptotic signal. Recent advances in our understanding of the KSHV genome and the many sequential and parallel signaling pathways it activates have identified several therapeutic targets. [37] Perhaps the most promising therapeutic targets in KS are the downstream signaling pathways upregulated by a viral G-protein coupled receptor (vGPCR). [38] Encoded by KSHV in the lytic phase of replication, vGPCR shares significant homology with the high-affinity interleukin (IL)-8 receptor, and its dysregulated expression contributes to oncogenesis. [39] The consequence of its activation is best highlighted by the fact that transgenic mice expressing vGPCR develop angioproliferative tumors resembling KS in multiple organs. These tumorigenic effects are potentially mediated through numerous cellular proliferation, transformation, proangiogenic and antiapoptotic signaling pathways, the most important of which appears to be the phosphatidylinositol 3-kinase (PI3K) pathway. [38] [39] [40] [41] [42] PI3K is a lipid kinase that activates Akt, a serine-threonine kinase that has multiple targets including the mammalian target of rapamycin (mTOR), a kinase that plays a crucial role in cell proliferation and survival in KS. [42, 43] The activation of this pathway and the implications of its inhibition have been well described in vGPCR-transfected cells and in AIDS-related KS samples. In vitro, cells expressing constitutively active vGPCR have high levels of activated Akt, inactivated TSC2 (a tumor suppressor which is inactivated by Akt), and activated mTOR. [44, 45] This has been reversed with either a PI3K inhibitor (LY 294002) or an mTOR inhibitor (sirolimus) both in vitro and in in vivo murine models, with accompanying decreased tumor growth. [45] As mentioned in section 4, all 15 patients with iatrogenic KS who developed lesions on ciclosporin-based immunosuppression regimens had complete clinical and histologic regression of KS in response to discontinuation of ciclosporin and initiation of treatment with sirolimus. [36] In addition, in skin biopsy specimens from kidney transplant recipients with Kaposi sarcoma, there was intense staining of mTOR pathway mediators -including expression of phosphorylated Akt, vascular endothelial growth factor (VEGF), VEGF receptor 2 (VEGFR2), and phosphorylated p70S6 kinase -compared with normal skin biopsies. [36] A clinical trial is underway to determine the safety and efficacy of sirolimus in AIDS-related KS. [46] Activation of mTOR has numerous effects, including enhancement of a proangiogenic signal through increased expression of VEGF. [47] In KS, not only VEGF but expressions of VEGFR2 and VEGFR3 are also seen and are deemed important for its development. [48] [49] [50] [51] [52] Furthermore, the expression of vGPCR in human umbilical vein endothelial cells leads to immortalization, which occurs with concomitant expression of VEGFR2 (KDR). [53] This further activates PI3K Akt mTOR and leads to increased secretion of VEGF, which enhances VEGFR2 activation. This autocrine loop enhances survival of these cells and is thought to be a major transforming mechanism. [53] Inhibition of VEGF, either through monoclonal antibodies (bevacizumab) or with small-molecule tyrosine kinase inhibitors (sorafenib, sunitinib), has proven clinical efficacy in many solid tumors, including breast cancer, renal cell carcinoma, lung cancer, and colon cancer. Currently, the use of VEGF inhibitors in the treatment of patients with KS is an area of active investigation, and National Cancer Institutesponsored clinical trials are ongoing with bevacizumab, [54] sunitinib, [55] and sorafenib.
[56]
Targeting of downstream effectors of the vGPCR in the treatment of KS, including PI3K, mTOR, or VEGF, offers considerable rationale and promise; however, downmodulation of the receptor activation itself may provide a more direct and effective strategy. IL-12 is a proinflammatory cytokine that promotes expression of the type I immune response, at least in part through stimulation of interferon (INF)-g production, and is known to mediate an antiangiogenic signal. [57] In addition, IL-12 upregulates INF-induced-protein-10 (IP-10), which is a known negative regulator of vGPCR, and IL-12 may thus inhibit vGPCR signal transduction through this mechanism. [58, 59] Given these properties, it is not surprising that IL-12 has been investigated as a potential treatment for KS. In a phase I exploratory study of patients with AIDS-related KS, 17 of 24 patients (70%) treated with higher doses of IL-12, near or above the maximum tolerated dose (MTD) of 500 ng kg, experienced a partial or complete response. [60] Following this, IL-12 was combined with PLD in a phase II study. In this trial, patients received both IL-12 and PLD for up to six cycles and then received IL-12 maintenance for up to 3 years. [61] Thirty (83%) of the 36 patients enrolled had a major clinical response, and the median progression-free survival was not reached during a median follow-up of over 4 years.
While targeting of mTOR and VEGF are promising therapeutic strategies, inhibition of other upregulated pathways in KS has been the focus of recently completed clinical trials. Based on the pathologic findings of increased expression of the platelet-derived growth factor receptor (PDGFR) and the receptor tyrosine kinase c-kit in KS, a pilot study with imatinib has been performed. [62] [63] [64] [65] [66] Imatinib is a small-molecule inhibitor of multiple tyrosine kinases, including bcr-abl, PDGFR, and c-kit. A total of ten patients with AIDS-related KS were treated with imatinib, and clinical and histologic responses were seen in four patients. [67] Finally, another promising therapeutic strategy for KS is the inhibition of matrix metalloproteinases (MMPs). MMPs are endopeptidases that assist in angiogenesis via degradation of extracellular matrix. While they play a role in normal angiogenesis and wound healing, several MMPs such as MMP2 and MMP9 are associated with malignancy, and both are expressed in KS. [68, 69] COL-3, a tetracycline, is a known MMP inhibitor, which has shown promising activity in a phase I trial in patients with advanced malignancies. [70] Based on MMP expression in KS, this phase I trial showed that COL-3 was well tolerated and had antitumor activity in patients with AIDS-related KS.
A subsequent phase II trial confirmed the antitumor activity of COL-3 against KS. [71] 
Conclusions
Over the past 10-15 years, the ability to molecularly target intricate pathways in cancer has been transformed from a hopeful idea into a definitive reality. This has revolutionized the way in which cancer is being treated, and AIDS-related malignancies are no exception. In particular, KS is an ideal example of a disease whose clinical characteristics inspired elegant bench research, which has translated into improved clinical decision making. Its association with immunodeficiency and certain regions stimulated investigators to search out a culprit infectious agent. Once discovered, elegant research on KSHV elucidated intricate sequential and parallel signaling pathways that could be inhibited by small-molecule tyrosine kinase inhibitors and antibodies to key cell surface receptors. In total, this has translated into a multifaceted therapeutic approach, which includes targeting the causal agent (KSHV), the deficient immune system (ie. HAART in AIDS-related KS), and the molecular pathways that fuel tumor growth and new blood vessel formation (as summarized in table I). Continued efforts remain essential in determining the optimal treatment for KS that will minimize toxicity and enhance patients' quality and quantity of life. It seems clear that the application of state-ofthe art bench and clinical research tools will help us achieve this now attainable goal. HAART = highly active antiretroviral therapy; HDAC = histone deacetylase; KSHV = KS-associated herpesvirus; MMP = metalloproteinase; mTOR = mammalian target of rapamycin; PDGFR = platelet-derived growth factor receptor; PLD = PEGylated liposomal doxorubicin; RR = response rate; TTP = time to progression; VEGF = vascular endothelial growth factor; VEGFR = VEGF receptor; vGPCR = viral G-protein coupled receptor.
